Larimar Therapeutics Inc
$ 3.69
31.32%
24 Feb - close price
- Market Cap 240,509,000 USD
- Current Price $ 3.69
- High / Low $ 4.01 / 3.55
- Stock P/E N/A
- Book Value 1.62
- EPS -1.96
- Next Earning Report 2026-03-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.43 %
- ROE -0.78 %
- 52 Week High 5.37
- 52 Week Low 1.61
About
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
Analyst Target Price
$14.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-12 | 2024-10-30 | 2024-08-07 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 | 2023-05-15 | 2023-03-14 |
| Reported EPS | -0.61 | -0.41 | -0.46 | -0.45 | -0.24 | -0.34 | -0.27 | -0.3 | -0.21 | -0.19 | -0.15 | -0.21 |
| Estimated EPS | -0.4128 | -0.4803 | -0.4091 | -0.3194 | -0.37 | -0.31 | -0.23 | -0.25 | -0.22 | -0.19 | -0.25 | -0.37 |
| Surprise | -0.1972 | 0.0703 | -0.0509 | -0.1306 | 0.13 | -0.03 | -0.04 | -0.05 | 0.01 | 0 | 0.1 | 0.16 |
| Surprise Percentage | -47.7713% | 14.6367% | -12.4419% | -40.8892% | 35.1351% | -9.6774% | -17.3913% | -20% | 4.5455% | 0% | 40% | 43.2432% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-23 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LRMR
2026-02-24 16:52:33
Larimar Therapeutics (NASDAQ:LRMR) shares surged after the FDA granted Breakthrough Therapy Designation for its Friedreich's ataxia treatment, nomlabofusp, for adults and children. This designation aims to accelerate the drug's development. Larimar plans to submit a Biologics License Application (BLA) in June 2026, targeting a U.S. launch in the first half of 2027, with topline data expected in Q2 2026 and a global Phase 3 trial commencing soon after.
2026-02-24 14:52:34
Larimar Therapeutics' stock (NASDAQ: LRMR) surged by 34.32% due to significant FDA designations and promising financial results. The company reported a substantial increase in cash to $90M but also a net income loss of $47M, attributed to strategic investments and R&D. Despite operational challenges, investors are optimistic about potential future gains and the company's strong current and leverage ratios.
2026-02-24 14:45:00
Larimar Therapeutics (LRMR) stock surged 28.5% after the FDA granted Breakthrough Therapy Designation for nomlabofusp, their Friedreich’s ataxia treatment. This designation is expected to accelerate its path to market, aligning with the company's planned Biologics License Application submission in June 2026 and targeted U.S. launch in early 2027. The news has boosted investor confidence, supported by positive analyst ratings and price targets.
2026-02-24 13:52:34
Larimar Therapeutics shares surged 35.6% in pre-market trading following the announcement that its neurological disease treatment received "Breakthrough Therapy" designation from the FDA. This designation indicates significant advantages in early clinical studies and is expected to expedite the drug's development and review process.
2026-02-24 13:07:00
Larimar Therapeutics' stock surged over 30% pre-market after the FDA granted Breakthrough Therapy Designation to its treatment, nomlabofusp, for Friedreich’s ataxia. The FDA also agreed that skin FXN levels could serve as a novel surrogate endpoint, supporting the planned Biologics License Application submission. This news, coupled with encouraging clinical data showing increased FXN levels and improvements across key clinical measures, led to a significant increase in retail investor sentiment and message volume for LRMR.
2026-02-24 11:52:34
Larimar Therapeutics has received FDA Breakthrough Therapy Designation for its drug nomlabofusp, intended for adults and children with Friedreich’s ataxia. The company plans to submit a Biologics License Application (BLA) for accelerated approval in June 2026, based on topline open-label study data expected in Q2 2026. Global Phase 3 screening is set to begin in Q2 2026, with a target U.S. launch in the first half of 2027 if approved.
